A new preclinical study reports that inhibiting complement factor B with iptacopan suppresses pancreatic cancer growth and reshapes the tumor immune environment in mouse models. The work positions complement pathway blockade as a potential combination lever to alter immune signaling within the tumor microenvironment. The findings add to a growing body of research connecting innate immune pathways with resistance mechanisms and tumor persistence in pancreatic ductal adenocarcinoma. While the excerpt does not specify a clinical translation plan, the focus on immune-environment remodeling aligns with ongoing interest in pairing immunomodulators with standard oncology regimens. For biotech strategy teams, complement inhibition represents both a mechanistic opportunity and a development risk area where translational consistency has varied across indications. This update strengthens the rationale for evaluating complement-targeting approaches in rational combinations.